From: Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
Independent centralized review
ORR (95%CI)
37.8(26.8–49.9)
CR
3(4.1)
VGPR
5(6.8)
PR
20(27.0)
SD
32(43.2)
PD
Not evaluable
9(12.1)a
TTR, months
1.84(0.95–2.35)
Median (95%CI) DOR
8.8(6.0–14.7)